Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 9476Neoplasms 6587Prostatic Neoplasms 4399Colorectal Neoplasms 3977Lung Neoplasms 3642Carcinoma, Non-Small-Cell Lung 3583Pancreatic Neoplasms 2478Carcinoma, Hepatocellular 2411Leukemia, Myeloid, Acute 2265Multiple Myeloma 2120Stomach Neoplasms 2108Neoplasm Metastasis 1911Head and Neck Neoplasms 1869Ovarian Neoplasms 1773Precursor Cell Lymphoblastic Leukemia-Lymphoma 1734Lymphoma 1729Brain Neoplasms 1699Rectal Neoplasms 1676Melanoma 1654Colonic Neoplasms 1629Leukemia 1500Uterine Cervical Neoplasms 1499Recurrence 1485Esophageal Neoplasms 1311Glioblastoma 1307Lymphoma, Non-Hodgkin 1204Leukemia, Lymphocytic, Chronic, B-Cell 1120Squamous Cell Carcinoma of Head and Neck 1109Urinary Bladder Neoplasms 1078Lymphoma, Follicular 1067

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced or Metastatic Gastric Adenocarcinoma × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡